Neumora Therapeutics (NASDAQ:NMRA) Downgraded to “Hold” Rating by Stifel Nicolaus
Stifel Nicolaus downgraded shares of Neumora Therapeutics (NASDAQ:NMRA – Free Report) from a buy rating to a hold rating in a research report released on Friday, Marketbeat reports. The firm currently has $2.00 price objective on the stock, down from their prior price objective of $6.00. Several other equities research analysts also recently commented on […]
Stifel Nicolaus downgraded shares of Neumora Therapeutics (NASDAQ:NMRA – Free Report) from a buy rating to a hold rating in a research report released on Friday, Marketbeat reports. The firm currently has $2.00 price objective on the stock, down from their prior price objective of $6.00. Several other equities research analysts also recently commented on […]
